Cargando…

Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma

Because immune checkpoint inhibitors have been approved for treating advanced urothelial carcinoma (UC), programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been widely used as companion or complementary diagnostic tests for predicting treatment outcomes. Because different clone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Tzu-Hao, Cheng, Wei, Wang, Yeh-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998202/ https://www.ncbi.nlm.nih.gov/pubmed/33807802 http://dx.doi.org/10.3390/diagnostics11030448

Ejemplares similares

PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype
por: Kim, Bohyun, et al.
Publicado: (2020)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count
por: Miyama, Yu, et al.
Publicado: (2018)

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022)

Reappraisal of waist circumference cutoff value according to general obesity
por: Kim, Kyung-Soo, et al.
Publicado: (2016)

SARCOPENIA ACCORDING TO BRAZILIAN AND EWGSOP 2 CUTOFFS: DATA FROM SARCOS
por: Menezes, Julia M, et al.
Publicado: (2019)

Fold change and p-value cutoffs significantly alter microarray interpretations
por: Dalman, Mark R, et al.
Publicado: (2012)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience
por: Nasr, Sarah, et al.
Publicado: (2023)

The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?
por: Kim, Beom Kyung
Publicado: (2021)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022)

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
por: Xie, Tong, et al.
Publicado: (2021)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
por: Mo, Shu-Fen, et al.
Publicado: (2023)

Role of immunotherapy in localized muscle invasive urothelial cancer
por: Kaur, Jasmeet, et al.
Publicado: (2021)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report
por: Yin, Huaqi, et al.
Publicado: (2022)

PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
por: Nechifor-Boilă, Ioan Alin, et al.
Publicado: (2021)

Concordance of expert clinicians’ interpretations of the newborn’s true physiological state
por: Zestic, Jelena, et al.
Publicado: (2021)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2020)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
por: Sanford, Thomas, et al.
Publicado: (2018)

Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible
por: Frydenlund, Noah, et al.
Publicado: (2018)

A Higher Cutoff for TSI Would Better Predict Recurrence in Patients With Graves’ Disease?
por: Fontes, Rosita, et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Individualized Cutoff Value of the Serum Carcinoembryonic Antigen Level According to TNM Stage in Colorectal Cancer
por: Ahn, Byung-Kwon
Publicado: (2013)

The Prevalence of Nocturia and Nocturnal Polyuria: Can New Cutoff Values Be Suggested According to Age and Sex?
por: Zumrutbas, Ali Ersin, et al.
Publicado: (2016)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2018)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

From Clone Selection to 80L Bioreactor Production: Better, Faster, Leaner
por: Clincke, Marie-Françoise, et al.
Publicado: (2015)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma
por: Hlaing, Sa Tin Myo, et al.
Publicado: (2023)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
por: Liu, Haoran, et al.
Publicado: (2020)

Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma
por: Yassaie, Omid, et al.
Publicado: (2021)

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
por: Maeda, Shingo, et al.
Publicado: (2022)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ba8ar0btpv700rgq6bpufba108